Obesity and metabolism related disorders are key therapeutic areas that have attracted global attention over recent years. Porsolt has in place a comprehensive range of models for obesity, impaired glucose tolerance, and diabetes to assist with the development of novel therapeutic agents for the treatment and reduction of risk factors associated with metabolic diseases.


STZ-Induced Diabetes model -Type I diabetes model

Sprague Dawley rats fed a standard diet (SD) and given a single administration of streptozotocin (STZ 45 mg/kg). Effects of subchronic treatment (from Day 24 to Day 28 post STZ) in selected diabetic rats.

Basal glycemia

OGTT at Day 28

> Additional parameters: plasma insulin, urinary volume, glomerular filtration rate, food/water intake

> References: Metformin, Insulin

Zucker Diabetic Fatty (ZDF) Rats - Type II diabetes model

The diabetic profile of ZDF rats, 10-16 weeks of age, is characterized by increased body weight, hyperglycemia, hyperinsulinemia, glucose intolerance increasing in time, hyperphagia, polydipsia, polyuria, decrease in glomerular filtration rate (GFR), high levels of cholesterol and triglycerides.

Basal blood glucose and plasma insulin in ZDF rats at 10 and 16 weeks old

OGTT in ZDF rats aged 10 and 16 weeks old: effects of sitagliptin